161 related articles for article (PubMed ID: 25917364)
1. Size, edge, and stage of NSCLC determine the release of CYFRA 21-1 in bloodstream.
Sertić Milić H; Franjević A; Bubanović G; Marušić A; Nikolić I; Puljić I
Wien Klin Wochenschr; 2015 Jun; 127(11-12):465-71. PubMed ID: 25917364
[TBL] [Abstract][Full Text] [Related]
2. High preoperative and postoperative levels of carcinoembryonic antigen and CYFRA 21-1 indicate poor prognosis in patients with pathological Stage I nonsmall cell lung cancer.
Duan X; Cui Y; Li H; Shi G; Wu B; Liu M; Chang D; Wang T; Kong Y
Indian J Cancer; 2015 Dec; 52 Suppl 3():E158-63. PubMed ID: 27453414
[TBL] [Abstract][Full Text] [Related]
3. Optimal cut-off values for CYFRA 21-1 expression in NSCLC patients depend on the presence of benign pulmonary diseases.
Xu RH; Liao CZ; Luo Y; Xu WL; Li K; Chen JX; Huang YF; Chen YC; Zhu L; Yuan WB
Clin Chim Acta; 2015 Feb; 440():188-92. PubMed ID: 25304744
[TBL] [Abstract][Full Text] [Related]
4. Comparison of cytokeratin 19 expression in tumor tissue and serum CYFRA 21-1 levels in non-small cell lung cancer.
Kosacka M; Jankowska R
Pol Arch Med Wewn; 2009; 119(1-2):33-7. PubMed ID: 19341176
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of serum C-reactive protein (CRP) and cytokeratin 19 fragments (Cyfra 21-1) but not carcinoembryonic antigen (CEA) in surgically treated patients with non-small cell lung cancer.
Szturmowicz M; Rudziński P; Kacprzak A; Langfort R; Bestry I; Broniarek-Samson B; Orłowski T
Pneumonol Alergol Pol; 2014; 82(5):422-9. PubMed ID: 25133810
[TBL] [Abstract][Full Text] [Related]
6. CYFRA 21-1 as a tool for distant metastasis detection in lung cancer.
Cabrera-Alarcon JL; Carrillo-Vico A; Santotoribio JD; Leon-Justel A; Sanchez-Gil R; Gonzalez-Castro A; Guerrero JM
Clin Lab; 2011; 57(11-12):1011-4. PubMed ID: 22239035
[TBL] [Abstract][Full Text] [Related]
7. Elevated serum levels of TPS and CYFRA 21-1 predict poor prognosis in advanced non-small-cell lung cancer patients treated with gefitinib.
Chen F; Luo X; Zhang J; Lu Y; Luo R
Med Oncol; 2010 Sep; 27(3):950-7. PubMed ID: 19830603
[TBL] [Abstract][Full Text] [Related]
8. Triple test with tumor markers CYFRA 21.1, HE4, and ProGRP might contribute to diagnosis and subtyping of lung cancer.
Korkmaz ET; Koksal D; Aksu F; Dikmen ZG; Icen D; Maden E; Onder S; Akbiyik F; Emri S
Clin Biochem; 2018 Aug; 58():15-19. PubMed ID: 29729229
[TBL] [Abstract][Full Text] [Related]
9. Serum Biomarkers Associated with Clinical Outcomes Fail to Predict Brain Metastases in Patients with Stage IV Non-Small Cell Lung Cancers.
Li BT; Lou E; Hsu M; Yu HA; Naidoo J; Zauderer MG; Sima C; Johnson ML; Daras M; DeAngelis LM; Fleisher M; Kris MG; Azzoli CG
PLoS One; 2016; 11(1):e0146063. PubMed ID: 26730601
[TBL] [Abstract][Full Text] [Related]
10. Correlation between EGFR gene mutation, cytologic tumor markers, 18F-FDG uptake in non-small cell lung cancer.
Cho A; Hur J; Moon YW; Hong SR; Suh YJ; Kim YJ; Im DJ; Hong YJ; Lee HJ; Kim YJ; Shim HS; Lee JS; Kim JH; Choi BW
BMC Cancer; 2016 Mar; 16():224. PubMed ID: 26979333
[TBL] [Abstract][Full Text] [Related]
11. CYFRA 21-1 as a prognostic and predictive marker in advanced non-small-cell lung cancer in a prospective trial: CALGB 150304.
Edelman MJ; Hodgson L; Rosenblatt PY; Christenson RH; Vokes EE; Wang X; Kratzke R
J Thorac Oncol; 2012 Apr; 7(4):649-54. PubMed ID: 22425913
[TBL] [Abstract][Full Text] [Related]
12. CYFRA 21-1 in the follow-up of inoperable non-small cell lung cancer patients treated with chemotherapy.
Ebert W; Muley T
Anticancer Res; 1999; 19(4A):2669-72. PubMed ID: 10470217
[TBL] [Abstract][Full Text] [Related]
13. CYFRA 21-1 as a Predictive Marker for Non-small Cell Lung Cancer Treated with Pemetrexed-based Chemotherapy.
Sone K; Oguri T; Nakao M; Kagawa Y; Kurowaka R; Furuta H; Fukuda S; Uemura T; Takakuwa O; Kanemitsu Y; Ohkubo H; Takemura M; Maeno K; Ito Y; Sato H; Muramatsu H; Niimi A
Anticancer Res; 2017 Feb; 37(2):935-939. PubMed ID: 28179355
[TBL] [Abstract][Full Text] [Related]
14. Serum CYFRA 21-1 in advanced stage non-small cell lung cancer: an early measure of response.
Vollmer RT; Govindan R; Graziano SL; Gamble G; Garst J; Kelley MJ; Christenson RH
Clin Cancer Res; 2003 May; 9(5):1728-33. PubMed ID: 12738727
[TBL] [Abstract][Full Text] [Related]
15. Cytokeratin-19 fragments, nucleosomes and neuron-specific enolase as early measures of chemotherapy response in non-small cell lung cancer.
Alm El-Din MA; Farouk G; Nagy H; Abd Elzaher A; Abo El-Magd GH
Int J Biol Markers; 2012 Jul; 27(2):e139-46. PubMed ID: 22467097
[TBL] [Abstract][Full Text] [Related]
16. Relationship between pretreatment levels of serum Cyfra 21.1, CEA and PET metabolic parameters in NSCLC.
Dogan I; Karyagar S; Karyagar SS; Kahraman C; Alver A
Ann Nucl Med; 2014 Nov; 28(9):829-35. PubMed ID: 24990528
[TBL] [Abstract][Full Text] [Related]
17. Performance characteristics of an automated assay for the quantitation of CYFRA 21-1 in human serum.
Patel JL; Erickson JA; Roberts WL; Grenache DG
Clin Biochem; 2010 Dec; 43(18):1449-52. PubMed ID: 20875814
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of Cyfra 21-1: a potential tumor marker for non-small cell lung carcinomas.
Karnak D; Ulubay G; Kayacan O; Beder S; Ibis E; Oflaz G
Lung; 2001; 179(1):57-65. PubMed ID: 11479694
[TBL] [Abstract][Full Text] [Related]
19. A retrospective analysis of serum tumor markers found in non-small cell lung cancer.
Hu Q; Xiao P; Li J; Yu P
J Cancer Res Ther; 2016; 12(1):117-20. PubMed ID: 27072222
[TBL] [Abstract][Full Text] [Related]
20. CYFRA 21-1 in the early diagnosis of recurrent disease in non small cell lung carcinomas (NSCLC).
Stieber P; Zimmermann A; Reinmiedl J; Müller C; Hoffmann H; Dienemann H
Anticancer Res; 1999; 19(4A):2665-8. PubMed ID: 10470216
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]